Duo Oncology unveils new corporate logo
Rebranded Website Highlights the company mission
PITTSBURGH (PRWEB) October 14, 2022 – Duo Oncology today unveiled a bold new corporate brand that represents the company’s novel approach to redefining treatment for patients with difficult-to-target tumors.
Founded in 2020, Duo Oncology began with the mission to transform the treatment landscape for patients with stroma-rich tumors. The stroma-rich diagnosis, a negative prognostic, applies to over 80% of pancreatic cancer patients. Duo aims to be the leading pharmaceutical developer of therapies that penetrate stromal tissue, which commonly surrounds and protects growing cancer cells. The company undertook a corporate rebranding and website redesign as a way to more effectively convey the innovative platform behind its pipeline of stroma-penetrating nanomedicines.
“As a pharmaceutical startup company developing new therapies in the ever-changing field of cancer medicine, it is important that our brand clearly convey the unique and potent aspects of our technology: ultrasmall nanomedicines that can traverse obstructive stromal tissue, a responsive chemistry that is sensitive to the tumor microenvironment, and a potent two drug payload that directly reaches cancer cells. Our new logo exemplifies the potential of our nanomedicine platform to provide hope for patients diagnosed with some of the hardest-to-treat cancers.”
Previous logo (left) undergoes a redesign (right)
A design rooted in effective drug delivery
The new logo (above, right) is a representation of Duo Oncology’s purpose and ambition to create safe and effective nanomedicines for patients with stroma-rich tumors. The two yellow dots in the logo’s center represent the duo of anti-cancer therapies co-delivered by our nanomedicine. Its outer shell is emblematic of our patent-pending polymer chemistry that self assembles to give Duo’s nanomedicines their ultrasmall size. These aspects combine with a bold new color to complement Duo Oncology’s bold new approach to redefining cancer treatment for patients suffering from difficult to treat tumors.
For more information about Duo Oncology and their ongoing nanomedicine development programs, visit the website.
# # #
About Duo Oncology: Duo Oncology’s mission is to redefine the treatment landscape for patients with stroma-rich tumors. The company develops high-potency nanomedicines that penetrate through a tumor's stromal tissue to reach growing cancer cells and extend the lives of, or even cure, cancer patients. Duo’s core innovation is a patent pending chemistry that ties together self-assembling DNA-like bases with environmentally sensitive linkers to form ultrasmall nanomedicines, which carry potent combination payloads all the way to growing cancer cells deep within tumors. The company’s lead nanomedicine (DUO-207, now in IND-enabling studies) treats solid tumors that respond to paclitaxel or gemcitabine therapy, such as pancreatic cancer, ovarian cancer, and cholangiocarcinoma. By using known active drug chemistries, DUO-207 offers a streamlined, de-risked development pathway that allows it to begin helping patients years sooner than bespoke therapies. Additional pipeline products use novel active agents to create powerful immunotherapies and precision medicines.